Cytek Biosciences, Inc.

Cytek Biosciences, Inc. Beats on EPS, Stock Down 7.84%

Cytek Biosciences reported a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 7.84%, suggesting that investors may have been disappointed by the lack of revenue information or future guidance. The absence of management commentary leaves uncertainty about the company's outlook.